{"id":70507,"date":"2026-07-23T21:53:59","date_gmt":"2026-07-23T13:53:59","guid":{"rendered":"https:\/\/flcube.com\/?p=70507"},"modified":"2026-07-23T21:54:01","modified_gmt":"2026-07-23T13:54:01","slug":"gsk-secures-early-fda-approval-for-jideytro-ros1-inhibitor-for-resistant-non-small-cell-lung-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70507","title":{"rendered":"GSK Secures Early FDA Approval for Jideytro \u2013 ROS1 Inhibitor for Resistant Non-Small Cell Lung Cancer"},"content":{"rendered":"\n

GlaxoSmithKline plc (GSK)<\/strong> (NYSE: GSK<\/a>) announced on July 22, 2026 that the U.S. Food and Drug Administration (FDA)<\/strong> has approved Jideytro (zidesamtinib)<\/strong>, a ROS1 selective inhibitor<\/strong>, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)<\/strong> who have received a prior ROS1 kinase inhibitor. The approval was granted ahead of the September 18, 2026 target action date<\/strong>, underscoring the therapy’s clinical urgency.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>GlaxoSmithKline plc (GSK) (NYSE: GSK)<\/td><\/tr>
Drug<\/strong><\/td>Jideytro (zidesamtinib)<\/td><\/tr>
Approval Date<\/strong><\/td>22 Jul 2026 (accelerated vs. 18 Sep 2026 target)<\/td><\/tr>
Indication<\/strong><\/td>ROS1-positive NSCLC post-prior ROS1 kinase inhibitor<\/td><\/tr>
Acquisition Source<\/strong><\/td>Nuvalent, Inc. (recently completed acquisition)<\/td><\/tr>
Target Population<\/strong><\/td>Adult patients with locally advanced or metastatic disease<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Clinical Differentiation<\/h2>\n\n\n\n

Mechanism of Action<\/h3>\n\n\n\n